- In May 2024, the Centers for Disease Control and Prevention (CDC) announced an updated blastomycosis surveillance initiative in endemic U.S. states to improve case tracking and treatment response. This program leverages advanced diagnostic reporting tools and real-time data collection to enhance early detection and improve public health responses. The initiative reflects a growing recognition of blastomycosis as a significant fungal threat and aims to reduce delays in diagnosis and treatment across high-risk regions
- In March 2024, Pfizer Inc. launched a clinical study evaluating a novel azole-based antifungal therapy targeting systemic fungal infections including blastomycosis. The investigational drug is designed to offer improved oral bioavailability and reduced resistance risk. This development underscores Pfizer's continued investment in antifungal R&D and its goal to expand treatment options for rare systemic mycoses through safer, more effective oral therapies
- In February 2024, Gilead Sciences, Inc. expanded access to its liposomal amphotericin B (AmBisome) formulation in several low- and middle-income countries through a new pricing and distribution strategy. This move aims to support hospitals treating severe blastomycosis cases with more affordable, less nephrotoxic IV formulations. The initiative reflects Gilead’s commitment to global fungal disease management and access equity
- In January 2024, Bio-Rad Laboratories, Inc. introduced a new rapid antigen detection kit for Blastomyces dermatitidis, offering faster diagnostic turnaround in suspected cases. The kit uses lateral flow technology and can deliver results within hours, enabling early therapeutic decisions. This launch highlights the growing demand for point-of-care fungal diagnostics and supports timely intervention in both endemic and travel-related blastomycosis cases
- In December 2023, Scynexis, Inc. received orphan drug designation from the U.S. FDA for ibrexafungerp for the treatment of blastomycosis. Ibrexafungerp is a first-in-class oral glucan synthase inhibitor with broad-spectrum antifungal activity. The designation provides regulatory incentives and underscores the need for novel oral therapies in managing serious endemic mycoses such as blastomycosis
